Reading LH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LH free→Reading LH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LH free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is neutral, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 20% above where it trades (it looks cheap on this basis); the read is fair. The top factors to watch include the potential for guidance cuts and the performance of sector bellwethers like TMO, DHR, and IDXX. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $264.93. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $265 LH trades at 16× p/e, below its 19× p/e peer median. Our $334 fair value sits above the price; high confidence. Analysts: $300–$334. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 21% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.93x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $4.78 → $4.77 (-0.2% / 30d). 7 raised, 5 cut, 10 covering analysts.
0 upgrades, 0 downgrades / 30d. 79% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$97.
How much price usually moves either way.
On a bad day, this stock has moved -$211.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,522.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: An increase in EPS guidance would show stronger profit expectations. This could boost investor confidence.
Confirms:Labcorp increases its 2026 Adjusted EPS guidance. It is now higher than before.
Disproves:Labcorp maintains or lowers its 2026 Adjusted EPS guidance.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$300.00 – $334.00 (median $313.00) · 4 analysts · as of 2026-05-01
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LH Labcorp | Above typical Show detailsSector percentile: 80 of 100 | fair | moderate |
CVS CVS Health | Typical Show detailsSector percentile: 64 of 100 | fair | moderate |
CI Cigna | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | moderate |
DGX Quest Diagnostics | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
DVA DaVita | Above typical Show detailsSector percentile: 86 of 100 | inexpensive | moderate |
25 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Labcorp aims to increase its 2026 Adjusted EPS guidance, reflecting strong operational performance.
Labcorp updates its 2026 revenue guidance to reflect improved performance and outlook.
Labcorp provides guidance for 2026 free cash flow, reflecting its financial strategy.
Why it matters: An increase in revenue guidance would signal better growth prospects. This could positively affect stock performance.
Confirms:Labcorp increases its 2026 revenue guidance. It is now above current estimates.
Disproves:Labcorp keeps its 2026 revenue guidance unchanged or lowers it.
Why it matters: A slowdown in revenue growth could mean problems for Labcorp's business.
Confirms:Q2 revenue growth reported below 5.0% year over year.
Disproves:Q2 revenue growth reported above 6.1% year over year.
Why it matters: Clear guidance on free cash flow shows how Labcorp manages its money and operations.
Confirms one read:Management gives free cash flow guidance above $1.36 billion for 2026.
Confirms the other:Management gives free cash flow guidance below $1.24 billion for 2026.
Why it matters: Providing free cash flow guidance would indicate strong cash generation. This is key for future investments.
Confirms:Labcorp issues a positive free cash flow guidance for 2026.
Disproves:Labcorp does not provide free cash flow guidance or issues a negative outlook.
Why it matters: Higher EPS guidance shows stronger earnings and more investor confidence in growth.
Confirms:Management raises 2026 Adjusted EPS guidance above what it is now.
Disproves:Management keeps or lowers the 2026 Adjusted EPS outlook.
Regulation FD Disclosure Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on April 9, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026 . A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
Entry into a Material Definitive Agreement. On March 20, 2026 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Results of Operations and Financial Condition